Your browser doesn't support javascript.
loading
Trajectories of vital signs in patients with COVID-19.
Pimentel, Marco A F; Redfern, Oliver C; Hatch, Robert; Young, J Duncan; Tarassenko, Lionel; Watkinson, Peter J.
Afiliación
  • Pimentel MAF; Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK.
  • Redfern OC; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
  • Hatch R; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK. Electronic address: robert.hatch@doctors.uk.net.
  • Young JD; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
  • Tarassenko L; Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK.
  • Watkinson PJ; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Resuscitation ; 156: 99-106, 2020 11.
Article en En | MEDLINE | ID: mdl-32918984
ABSTRACT

BACKGROUND:

The global pandemic of coronavirus disease 2019 (COVID-19) has placed a huge strain on UK hospitals. Early studies suggest that patients can deteriorate quickly after admission to hospital. The aim of this study was to model changes in vital signs for patients hospitalised with COVID-19.

METHODS:

This was a retrospective observational study of adult patients with COVID-19 admitted to one acute hospital trust in the UK (CV) and a cohort of patients admitted to the same hospital between 2013-2017 with viral pneumonia (VI). The primary outcome was the start of continuous positive airway pressure/non-invasive positive pressure ventilation, ICU admission or death in hospital. We used non-linear mixed-effects models to compare changes in vital sign observations prior to the primary outcome. Using observations and FiO2 measured at discharge in the VI cohort as the model of normality, we also combined individual vital signs into a single novelty score.

RESULTS:

There were 497 cases of COVID-19, of whom 373 had been discharged from hospital. 135 (36.2%) of patients experienced the primary outcome, of whom 99 died in hospital. In-hospital mortality was over 4-times higher in the CV than the VI cohort (26.5% vs 6%). For those patients who experienced the primary outcome, CV patients became increasingly hypoxaemic, with a median estimated FiO2 (0.75) higher than that of the VI cohort (estimated FiO2 of 0.35). Prior to the primary outcome, blood pressure remained within normal range, and there was only a small rise in heart rate. The novelty score showed that patients with COVID-19 deteriorated more rapidly that patients with viral pneumonia.

CONCLUSIONS:

Patients with COVID-19 who deteriorate in hospital experience rapidly-worsening respiratory failure, with low SpO2 and high FiO2, but only minor abnormalities in other vital signs. This has potential implications for the ability of early warning scores to identify deteriorating patients.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neumonía Viral / Triaje / Infecciones por Coronavirus / Signos Vitales / Betacoronavirus Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Resuscitation Año: 2020 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neumonía Viral / Triaje / Infecciones por Coronavirus / Signos Vitales / Betacoronavirus Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Resuscitation Año: 2020 Tipo del documento: Article País de afiliación: Reino Unido
...